Treatment of chronic hepatitis C with interferon-alpha by monitoring the response according to viraemia

J Viral Hepat. 1997 Mar;4(2):107-12. doi: 10.1111/j.1365-2893.1997.tb00212.x.

Abstract

In chronic hepatitis C (HCV) infection, treatment with interferon is associated with a rather low rate of sustained response and many treated patients do not achieve significant benefit. Efforts have therefore been made to identify non-responders as early as possible to avoid unjustified costs and side-effects. We treated 106 cases of HCV with an algorithm based on the results of sequential alanine aminotransferase (ALT) and HCV RNA determinations, using an initial dose of 6 MU thrice weekly for 4 months, and modified the subsequent treatment according to the biochemical and virological profile. Thirty-three out of 48 patients (68.7%) who were HCV RNA negative with normal ALT at 4 months after initiation of treatment were sustained responders when treated for an additional 4-month period with a reduced 3 MU dose, while sustained response was achieved in 12.5% of HCV RNA positive patients treated with a higher dosage and for a more prolonged period of time. Our findings indicate that HCV RNA monitoring during interferon therapy may be useful in modifying of the treatment schedule for the individual patient.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Alanine Transaminase / blood
  • Antiviral Agents / therapeutic use*
  • Chronic Disease
  • Female
  • Follow-Up Studies
  • Hepacivirus / genetics
  • Hepacivirus / isolation & purification*
  • Hepatitis C / drug therapy
  • Hepatitis C / virology*
  • Humans
  • Interferon-alpha / therapeutic use*
  • Male
  • Middle Aged
  • RNA, Viral / analysis
  • Treatment Outcome
  • Viremia*

Substances

  • Antiviral Agents
  • Interferon-alpha
  • RNA, Viral
  • Alanine Transaminase